ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis

Company Overview

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Key Stats

• Today's Range: $0.48 to $0.53
• 50-Day Range: $2.53 to $3.58
• 52-Week Range: $3.52 to $91.00
• Volume: 48,091 shs
• Average Volume: 432,822 shs
• Market Capitalization: $392,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CTRV Stock Analysis - Frequently Asked Questions

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) announced its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.68.

When did ContraVir Pharmaceuticals' stock split?

ContraVir Pharmaceuticals's stock reverse split on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of ContraVir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Palatin Technologies (PTN) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 5/13/2016
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CTRV
• CUSIP: N/A
• CIK: 1583771
• Web: www.contravir.com
• Phone: 732-902-4000
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,450,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -4,810.77%
• Return on Assets: -130.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.55
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.80 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 800,000
• Free Float: N/A
• Market Cap: $392,000.00
• Optionable: Not Optionable
• Beta: 1.16